HIV-1 prophylactic vaccines: state of the art
The quest for an effective HIV-1 vaccine began early in the course of the HIV pandemic. Over time, the paradigm has evolved from B cell- towards T cell-based vaccines. Results from initial Phase II/III trials have been disappointing; however, while modest, the unexpected results of the Phase II/III...
Saved in:
Main Authors: | Jean-Daniel Lelièvre (Author), Yves Lévy (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2016-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines
by: Mathieu Surenaud, et al.
Published: (2017) -
Current progress in the development of a prophylactic vaccine for HIV-1
by: Lena J Gamble, et al.
Published: (2010) -
Application of prophylactic vaccines in the elderly
by: Bufan Biljana
Published: (2019) -
Multiscale Systems‐Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV‐1
by: S Duwal, et al.
Published: (2016) -
An overview of adjuvants utilized in prophylactic vaccine formulation as immunomodulators
by: Nidhi Chauhan, et al.
Published: (2017)